RU2019128494A - Method for activating cytotoxic lymphocytes - Google Patents

Method for activating cytotoxic lymphocytes Download PDF

Info

Publication number
RU2019128494A
RU2019128494A RU2019128494A RU2019128494A RU2019128494A RU 2019128494 A RU2019128494 A RU 2019128494A RU 2019128494 A RU2019128494 A RU 2019128494A RU 2019128494 A RU2019128494 A RU 2019128494A RU 2019128494 A RU2019128494 A RU 2019128494A
Authority
RU
Russia
Prior art keywords
gly
lymphocytes
result
cells
increase
Prior art date
Application number
RU2019128494A
Other languages
Russian (ru)
Other versions
RU2019128494A3 (en
RU2751837C2 (en
Inventor
Сергей Иванович Черныш
Дмитрий Валентинович Тулин
Original Assignee
Сергей Иванович Черныш
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сергей Иванович Черныш filed Critical Сергей Иванович Черныш
Priority to RU2019128494A priority Critical patent/RU2751837C2/en
Publication of RU2019128494A3 publication Critical patent/RU2019128494A3/ru
Publication of RU2019128494A publication Critical patent/RU2019128494A/en
Application granted granted Critical
Publication of RU2751837C2 publication Critical patent/RU2751837C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Claims (23)

1. Способ активации цитотоксических лимфоцитов, включающий обработку клеток крови пептидом, содержащим аминокислотный сиквенс His-Gly-Val-Ser-Gly-Trp-Gly-Gln-His-Gly-Thr-His-Gly (SEQ ID №1), или его фармацевтически приемлемыми солями, или эфирами, или амидами в концентрации, усиливающей способность цитотоксических лимфоцитов лизировать трансформированные клетки организма1. A method of activating cytotoxic lymphocytes, comprising treating blood cells with a peptide containing the amino acid sequence His-Gly-Val-Ser-Gly-Trp-Gly-Gln-His-Gly-Thr-His-Gly (SEQ ID No. 1), or pharmaceutically acceptable salts, or esters, or amides at a concentration that enhances the ability of cytotoxic lymphocytes to lyse transformed body cells 2. Способ по п. 1, в котором пептид His-Gly-Val-Ser-Gly-Trp-Gly-Gln-His-Gly-Thr-His-Gly (SEQ ID №1) входит в состав химического вещества, которое не является природным белком или пептидом2. The method of claim 1, wherein the peptide His-Gly-Val-Ser-Gly-Trp-Gly-Gln-His-Gly-Thr-His-Gly (SEQ ID No. 1) is included in a chemical that is not is a natural protein or peptide 3. Способ по п. 1, в котором трансформированные клетки организма являются клетками рака3. The method according to claim 1, wherein the transformed body cells are cancer cells 4. Способ по п. 3, в котором клетки рака являются клетками рака легких4. The method of claim 3, wherein the cancer cells are lung cancer cells 5. Способ по п. 3, в котором клетки рака являются клетками рака шейки матки5. The method of claim 3, wherein the cancer cells are cervical cancer cells 6. Способ по п. 3, в котором клетки рака являются клетками лейкоза6. The method of claim 3, wherein the cancer cells are leukemia cells 7. Способ по п. 1, в котором трансформированные клетки организма инфицированы вирусами7. The method according to claim 1, wherein the transformed body cells are infected with viruses 8. Способ по п. 7, в котором вирус является вирусом папилломы человека8. The method of claim 7, wherein the virus is human papillomavirus 9. Способ по п. 1, результатом которого является активация NK лимфоцитов9. The method according to claim 1, the result of which is the activation of NK lymphocytes 10. Способ по п. 1, результатом которого является активация Т лимфоцитов10. The method according to claim 1, the result of which is the activation of T lymphocytes 11. Способ по п. 1, результатом которого является увеличение доли лимфоцитов, продуцирующих интерферон-гамма11. The method according to claim 1, the result of which is an increase in the proportion of lymphocytes producing interferon-gamma 12. Способ по п. 1, результатом которого является увеличение доли лимфоцитов, экспрессирующих активационный рецептор CD2512. The method according to claim 1, the result of which is an increase in the proportion of lymphocytes expressing the activation receptor CD25 13. Способ по п. 1, результатом которого является увеличение доли лимфоцитов, экспрессирующих активационный рецептор CD6913. The method according to claim 1, the result of which is an increase in the proportion of lymphocytes expressing the activation receptor CD69 14. Способ по п. 1, результатом которого является увеличение доли лимфоцитов, экспрессирующих активационный рецептор NKG2D14. The method according to claim 1, the result of which is an increase in the proportion of lymphocytes expressing the activation receptor NKG2D 15. Способ по п. 1, результатом которого является увеличение доли лимфоцитов, экспрессирующих активационный рецептор CD22615. The method according to claim 1, the result of which is an increase in the proportion of lymphocytes expressing the activation receptor CD226 16. Способ по п. 1, результатом которого является снижение доли лимфоцитов, экспрессирующих ингибирующие рецепторы семейства KIR16. The method according to claim 1, the result of which is a decrease in the proportion of lymphocytes expressing inhibitory receptors of the KIR family 17. Способ по п. 16, в котором ингибирующий рецептор семейства KIR является KIR2DL3, KIR3DL1, KLRG117. The method of claim 16, wherein the KIR family inhibitory receptor is KIR2DL3, KIR3DL1, KLRG1 18. Способ по п. 1, в котором лимфоциты обрабатывают путем введения пептида His-Gly-Val-Ser-Gly-Trp-Gly-Gln-His-Gly-Thr-His-Gly (SEQ ID №1) в кровь пациента18. The method according to claim 1, wherein the lymphocytes are treated by introducing the peptide His-Gly-Val-Ser-Gly-Trp-Gly-Gln-His-Gly-Thr-His-Gly (SEQ ID No. 1) into the patient's blood 19. Способ по п. 1, в котором лимфоциты обрабатывают путем интратуморального введения пептида His-Gly-Val-Ser-Gly-Trp-Gly-Gln-His-Gly-Thr-His-Gly (SEQ ID №1)19. The method of claim 1, wherein the lymphocytes are treated by intratumoral administration of the peptide His-Gly-Val-Ser-Gly-Trp-Gly-Gln-His-Gly-Thr-His-Gly (SEQ ID No. 1) 20. Способ по п. 1, в котором лимфоциты выделяют из периферической крови и инкубируют в питательной среде, содержащей пептид His-Gly-Val-Ser-Gly-Trp-Gly-Gln-His-Gly-Thr-His-Gly (SEQ ID №1)20. The method of claim 1, wherein the lymphocytes are isolated from peripheral blood and incubated in a nutrient medium containing the peptide His-Gly-Val-Ser-Gly-Trp-Gly-Gln-His-Gly-Thr-His-Gly (SEQ ID No. 1) 21. Применение способа по п. 1 для повышения чувствительности лимфоцитов к интерлейкину-1221. Application of the method according to claim 1 to increase the sensitivity of lymphocytes to interleukin-12 22. Применение способа по п. 1 для повышения чувствительности лимфоцитов к интерлейкину-222. Application of the method according to claim 1 to increase the sensitivity of lymphocytes to interleukin-2 23. Применение способа по п. 1 для поддержания популяции NK клеток в функционально активном состоянии в процессе цитотоксической реакции с трансформированными клетками23. Application of the method according to claim 1 for maintaining a population of NK cells in a functionally active state during a cytotoxic reaction with transformed cells
RU2019128494A 2019-09-10 2019-09-10 Method for activation of cytotoxic lymphocytes RU2751837C2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2019128494A RU2751837C2 (en) 2019-09-10 2019-09-10 Method for activation of cytotoxic lymphocytes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2019128494A RU2751837C2 (en) 2019-09-10 2019-09-10 Method for activation of cytotoxic lymphocytes

Publications (3)

Publication Number Publication Date
RU2019128494A3 RU2019128494A3 (en) 2021-03-10
RU2019128494A true RU2019128494A (en) 2021-03-10
RU2751837C2 RU2751837C2 (en) 2021-07-19

Family

ID=74857104

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019128494A RU2751837C2 (en) 2019-09-10 2019-09-10 Method for activation of cytotoxic lymphocytes

Country Status (1)

Country Link
RU (1) RU2751837C2 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA004879B1 (en) * 2001-12-28 2004-08-26 Открытое акционерное общество "Аллоферон" Allopherons-immunomodulatory peptides
RU2267496C2 (en) * 2004-01-15 2006-01-10 Сергей Иванович Черныш Anti-tumor and antiviral peptides
RU2454221C2 (en) * 2010-07-06 2012-06-27 Общество с ограниченной ответственностью "Завод Медсинтез" Method for preparing lyophilised antiviral agent

Also Published As

Publication number Publication date
RU2019128494A3 (en) 2021-03-10
RU2751837C2 (en) 2021-07-19

Similar Documents

Publication Publication Date Title
Younan et al. Positive selection of mC46-expressing CD4+ T cells and maintenance of virus specific immunity in a primate AIDS model
US7354575B2 (en) Method and pharmaceutical composition for treating inflammation
Alfano et al. New players in cytokine control of HIV infection
Iwashiro et al. CD4+ T cells and gamma interferon in the long-term control of persistent Friend retrovirus infection
Mitani et al. Suppressive effect on polyclonal B-cell activation of a synthetic peptide homologous to a transmembrane component of oncogenic retroviruses.
Misumi et al. IFN-λ exerts opposing effects on T cell responses depending on the chronicity of the virus infection
CN109620954B (en) Composition for activating latent HIV virus and application thereof
US20150105333A1 (en) Latent human immunodeficiency virus reactivation
Suzuki et al. Determinant in human immunodeficiency virus type 1 for efficient replication under cytokine-induced CD4+ T-helper 1 (Th1)-and Th2-type conditions
US20190367587A1 (en) Vc-car molecule and use thereof in removing hiv-1 infected cells
CN109836496A (en) It is a kind of to target the single-chain antibody of CD317, Chimeric antigen receptor T cell and its preparation method and application
Roigas et al. Heat shock protein (HSP72) surface expression enhances the lysis of a human renal cell carcinoma by IL-2 stimulated NK cells
Nunnari et al. IL-7 as a potential therapy for HIV-1-infected individuals
Sivanandham et al. Nonhuman primate testing of the impact of different regulatory T cell depletion strategies on reactivation and clearance of latent simian immunodeficiency virus
RU2019128494A (en) Method for activating cytotoxic lymphocytes
AU660422B2 (en) Pathogen-specific CTL therapy
Lee et al. Cytotoxic activity against maedi-visna virus-infected macrophages
CN107974460B (en) Chimeric antigen receptor gene aiming at HIV-1, plasmid, T cell, kit and application with gene
US20140295012A1 (en) Latent human immunodeficiency virus reactivation
ROSZTÓCZY et al. Effects of interferons-α,-β, and-γ on human interleukin-2 production
SEKO et al. RESTRICTED USAGE OF T‐CELL RECEPTOR Vα GENES IN INFILTRATING CELLS IN MURINE HEARTS WITH ACUTE MYOCARDITIS CAUSED BY COXSACKIE VIRUS B3
Ascher et al. AIDS as immune system activation: key questions that remain
Mealey et al. Failure of low-dose recombinant human IL-2 to support the survival of virus-specific CTL clones infused into severe combined immunodeficient foals: lack of correlation between in vitro activity and in vivo efficacy
US9790255B2 (en) Transactivator of transcription (TAT) proteins and preparation method
Flynn et al. Role of macrophages in the immunopathogenesis of HIV-1 infection

Legal Events

Date Code Title Description
HE9A Changing address for correspondence with an applicant
HZ9A Changing address for correspondence with an applicant
PC41 Official registration of the transfer of exclusive right

Effective date: 20211028